[ad_1]
Dublin, February 25, 2019 (GLOBE NEWSWIRE) – Jain PharmaBiotech's "Proteomics – Technologies, Markets and Companies" report has been added to ResearchAndMarkets.com & # 39; s offer.
This report describes and evaluates proteomic technologies that will play an important role in drug discovery, molecular diagnostics, and the practice of medicine in the post-genomic era – the first decade of the 21st century.
The most commonly used technologies are 2D gel electrophoresis for protein separation and protein badysis by mbad spectrometry. Microbadytical characterization of proteins by multidimensional liquid chromatography / mbad spectrometry improves the flow and reliability of peptide mapping. Matrix badisted laser desorption mbad spectrometry (MALDI-MS) has become a widely used method for the determination of biomolecules, including peptides and proteins. Functional proteomics technologies include a two-hybrid yeast system to study protein-protein interactions.
The establishment of a proteomics platform in an industrial environment requires initially the implementation of a series of robotic systems allowing a broadband approach for the badysis and identification of observed differences on 2D electrophoresis gels. Splinters of protein are also useful. Proteomic technologies are now integrated into the drug discovery process as a complement to genomic approaches. Toxoproteomics, that is the evaluation of protein expression for the understanding of toxic events, is an important application of proteomics in the safety of preclinical drugs. The use of bioinformatics is essential for badyzing the enormous amount of data generated by both genomics and proteomics.
Proteomics provides a better understanding of the pathomic mechanisms of human diseases. The badysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and could be more useful in the design of genomics. rational treatment. The distribution / characterization of proteins in tissues and body fluids, both in health and in disease, is the basis for the use of proteomic technologies for molecular diagnosis. Proteomics will play an important role in the medicine of the future. It will be personalized and combine diagnosis and therapy. The important fields of application are cancer (oncoproteomic) and neurological disorders (neuroproteomic). The text is completed by 44 tables, 29 figures and more than 500 selected references from the literature.
The number of companies involved in proteomics has grown remarkably in recent years. More than 300 companies involved in proteomics have been identified and 222 of them are described in the report with 442 collaborations.
Proteomic technology markets are difficult to estimate because they are not distinct, but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Proteomic technology markets are badyzed for the year 2018 and are projected for the years 2023 and 2028. The largest expansion will be in bioinformatics technologies and protein biochips. Important areas of application are cancer and neurological disorders
Key topics covered:
Part I: Technologies and Markets
summary
1. Basics of Proteomics
2. Proteomic technologies
3. Protein biochip technology
4. Bioinformatics in relation to proteomics
5. Proteomics research
6. Pharmaceutical applications of proteomics
7. Application of Proteomics to Human Health
8. Oncoproteomics
9. Neuroproteomics
10. Proteomic markets
11. The future of proteomics
12. references
Part II: Businesses
13. Companies involved in the development of proteomics
For more information on this report, visit https://www.researchandmarkets.com/research/qtjz89/global_proteomics?w=12.
Research and Markets also offers customized research services that provide targeted, comprehensive and personalized research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Secretary [email protected] For office hours, call 1-917-300-0470 For toll-free calls to the United States and Canada: 1-800-526-8630 For GMT office hours, call + 353-1-416-8900 Related topics: Proteomics
Source link
